Altesa's Vapendavir Shatters Antiviral Dogma, Offers Hope for COPD

COLLEGE PARK, Ga. – March 19, 2026 – A potential paradigm shift in the fight against common respiratory viruses is on the horizon, offering new hope to millions suffering from chronic lung diseases. Altesa BioSciences, a clinical-stage pharmaceutical company, announced that its investigational antiviral drug, vapendavir, has demonstrated unprecedented activity against a strain of rhinovirus previously thought to be untreatable by its class of drugs. The groundbreaking findings will be presented at the prestigious 39th International Conference on Antiviral Research (ICAR2026) in Prague this spring.

A Scientific Breakthrough Against the Common Cold Virus

The research challenges a long-held belief in virology. Rhinoviruses (RVs), the primary cause of the common cold, are classified into three species: RV-A, RV-B, and RV-C. While all can cause illness, they can trigger life-threatening exacerbations in people with underlying conditions like Chronic Obstructive Pulmonary Disease (COPD) and asthma. For years, the scientific community believed that the RV-C species was insensitive to capsid inhibitors, a class of antiviral drugs designed to block a virus from entering and replicating within human cells.

Altesa's new data turns this assumption on its head. The company will present the first-ever preclinical and clinical evidence showing that vapendavir, a capsid inhibitor, is effective against all three rhinovirus species, including RV-C. The oral presentation, titled "Vapendavir, a Rhinovirus Capsid Inhibitor, Exhibits Activity Against Type C Rhinoviruses," will be delivered by Katherine Squires, PhD, Altesa's Vice President for Research and Translational Science. Dr. Squires brings a wealth of experience to the role, with a doctorate in Molecular Pharmacology and a history of leading nonclinical antiviral programs.

Further analysis revealed that not only vapendavir but also its major metabolite, now designated as a new chemical entity called ALT-001, possess direct antiviral activity against the full spectrum of rhinoviruses. This dual-action mechanism strengthens the drug's potential as a potent, broad-spectrum therapy against the most common viral triggers of respiratory distress.

New Hope for Vulnerable Lungs

For the millions living with COPD and asthma, a simple cold is anything but simple. Rhinovirus infections are the single most identified cause of acute exacerbations in COPD patients, accounting for over 45% of these dangerous flare-ups. These events lead to a severe worsening of symptoms, a decline in lung function, frequent hospitalizations, and a significantly reduced quality of life. The economic burden is immense, with the annual direct cost of COPD in the U.S. soaring to approximately $50 billion, much of it driven by costly hospital stays for exacerbations.

Vapendavir aims to break this devastating cycle. By directly targeting the viral cause, the drug has the potential to fundamentally change how these conditions are managed. Altesa has stated that if approved, vapendavir could prevent up to 50% of COPD exacerbations. Such a reduction would represent a monumental leap forward, drastically improving patient outcomes and alleviating a significant strain on global healthcare systems.

Prior Phase 2 studies have already provided a glimpse of this potential. In a controlled study where COPD patients were experimentally infected with rhinovirus, those treated with vapendavir showed improved respiratory symptoms, a shorter duration of illness, reduced viral load, and preserved function in the small airways of the lungs compared to those on placebo.

Charting a Path Through Clinical Development

Building on this promising data, Altesa BioSciences is advancing vapendavir into late-stage clinical trials. The company is launching its pivotal Phase 2B Cardinal Study, a large-scale, multinational effort designed to provide definitive evidence of the drug's efficacy in a real-world setting. The study will enroll 900 people with COPD across the United States and the United Kingdom who are experiencing a rhinovirus infection.

Participants will be randomized to receive one of two doses of vapendavir or a placebo. The trial's primary goal is to measure improvement in respiratory symptoms using established patient-reported outcome tools. Investigators will also closely monitor the time it takes for symptoms to resolve, along with changes in quality of life, healthcare utilization, and lung function. The robust design of the Cardinal Study underscores the company's confidence in vapendavir and is a critical step toward potential regulatory approval.

An Emerging Leader in a Competitive Field

While the global market for rhinovirus treatments is projected to reach over $3 billion by 2032, there are currently no specifically approved antiviral drugs for rhinovirus infections. Treatment has largely been limited to managing symptoms. This leaves a significant unmet medical need that vapendavir is uniquely positioned to fill. As the only direct-acting antiviral targeting rhinovirus currently in human clinical trials, it represents a potential first-in-class therapy.

Steering Altesa BioSciences through this competitive landscape is a leadership team with deep experience in public health and regulatory science. The company's CEO is Dr. Brett Giroir, whose distinguished career includes serving as the 16th U.S. Assistant Secretary for Health, acting FDA Commissioner, and the White House's "COVID-19 Testing Czar" during the pandemic. His four-star admiral rank in the U.S. Public Health Service Commissioned Corps further highlights a career dedicated to medical science and public service.

This leadership, combined with the breakthrough science behind vapendavir, positions Altesa as a formidable player in the respiratory medicine space. The upcoming presentation at ICAR is not just a scientific update but a signal of the drug's broad potential.

"We are honored to present our novel data at ICAR, the premier international conference for antiviral research," said Dr. Brett Giroir in a statement. "In addition to advancing our fundamental understanding of the clinical pharmacology of vapendavir, these new findings strongly support the expansion of vapendavir potential indications to new patient groups, new diseases, and new treatment paradigms including prophylaxis."